Jobs
-
Receptor Life Sciences (RLS) has published data from a Phase 1 PK trial of its RLS103 dry powder cannabidiol (CBD) in the Journal of Pharmaceutical Sciences demonstrating significantly greater bioavailability for the inhaled CBD than for… Read more . . .
-
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and… Read more . . .
-
Virpax Pharmaceuticals said that it is encouraged by the FDA response to its IND for MMS019 “high-density molecular masking spray” which the company is developing as an anti-viral barrier. According to Virpax, the company now intends… Read more . . .
-
Tiziana Life Sciences has published results from a pilot study of its intranasal Foralumab in mild to moderate COVID-19 demonstrating that nasal administration of the human anti-CD3 monoclonal antibody was well tolerated and significantly reduced… Read more . . .
-
Aptar Pharma will have 12 months to decide whether to exercise an exclusive option to acquire worldwide rights to Pharmaxis’s high payload Orbital dry powder inhaler under a new agreement, the company said. The Orbital… Read more . . .
-
According to a LinkedIn post by generic device maker Merxin, the FDA has indicated that Merxin’s MRX004 soft mist inhaler is suitable for an ANDA submission for a generic version of Boehringer Ingelheim’s Spiriva Respimat… Read more . . .
-
Philip Morris International (PMI) has acquired inhaled drug developer OtiTopic, as “part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory… Read more . . .
-
Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma’s OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes… Read more . . .
-
According to ReCode Therapeutics, studies of its nebulized lipid nanoparticle DNAI1 mRNA therapy for the treatment of primary ciliary dyskinesia in non-human primates demonstrated that a single dose of the mRNA could be delivered successfully… Read more . . .
-
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden